Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advances in genomics and proteomics
3.2.1.2 Rising prevalence of chronic diseases
3.2.1.3 Growing demand for targeted therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High development costs
3.2.2.2 Regulatory complexities
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates & Forecast, By Biomarker Type, 2021-2032 ($ Mn)
5.1 Key trends
5.2 Genomic
5.3 Proteomics
5.4 Metabolic
5.5 Other biomarker types
Chapter 6 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)
6.1 Key trends
6.2 Early detection/screening
6.3 Diagnosis
6.4 Treatment selection
6.5 Monitoring
6.6 Other applications
Chapter 7 Market Estimates & Forecast, By Disease Indication, 2021-2032 ($ Mn)
7.1 Key trends
7.2 Oncology
7.3 Neurology
7.4 Diabetes
7.5 Autoimmune diseases
7.6 Cardiology
7.7 Other indications
Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)
8.1 Key trends
8.2 Hospitals and clinics
8.3 Pharmaceutical and biotechnology companies
8.4 Diagnostic labs
8.5 Other end users
Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Bio-Rad Laboratories
10.3 Danaher
10.4 EKF Diagnostics Holdings
10.5 F. Hoffmann-La Roche
10.6 Illumina
10.7 Lifesign
10.8 Merck
10.9 Myriad Genetics
10.10 QIAGEN
10.11 Signosis
10.12 Singulex
10.13 Thermo Fisher Scientific
